62814-45-3

Basic information

• Product Name: 1,3-Benzenedicarboxylic acid, 5-[(methylsulfonyl)amino]-, dimethyl ester
• CAS NO: 62814-45-3
• Molecular Formula: C11H13NO6S
• Molecular Weight: 287.293
• Mol File: 62814-45-3.mol

Chemical Properties

• CAS DataBase Reference: 1,3-Benzenedicarboxylic acid, 5-[(methylsulfonyl)amino]-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenedicarboxylic acid, 5-[(methylsulfonyl)amino]-, dimethyl ester(62814-45-3)
• EPA Substance Registry System: 1,3-Benzenedicarboxylic acid, 5-[(methylsulfonyl)amino]-, dimethyl ester(62814-45-3)

Safety Data

• Hazardous Substances Data: 62814-45-3(Hazardous Substances Data)

Usage

Group

Phthalate esters

Common Uses

Plasticizer in the production of vinyl flooring
Adhesives
Synthetic leather

Health Hazards

Disruption of hormone function
Potential reproductive and developmental toxicity

Adverse Effects

Liver damage
Kidney damage
Respiratory system issues

Regulatory Scrutiny

Increasing due to health and environmental concerns

Limitations

Restrictions on the use of this chemical in certain applications due to its potential hazards

Upstream product

• 99-27-4 dimethyl 5-aminoisophthalate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 911789-43-0 C₁₇H₁₇NO₆S 
• 868286-91-3 C₃₃H₃₈FN₅O₆S 
• 868286-89-9 C₃₃H₃₈FN₅O₅S₂ 
• 868287-32-5 C₃₄H₃₉FN₄O₆S 
• 868287-24-5 C₂₇H₃₉N₃O₇SSi 
• 868287-28-9 C₂₇H₃₇N₃O₈S 
• 868286-26-4 (R)-methyl-3-({2-[2-(tert-butylcarbamate)-2-methyl-3-phenylpropanoyl]hydrazino}carbonyl)-5-[methyl(methylsulfonyl)amino]benzoate 
• 868287-25-6 C₂₇H₃₇N₃O₆SSi 
• 868286-50-4 tert-butyl [1-(5-{3-{[methoxy(methyl)amino]carbonyl}-5-[methyl(methylsulfonyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)-1-(1R)-methyl-2-phenylethyl]carbamate 
• 868286-87-7 C₂₆H₃₂N₄O₆S₂ 
• 868286-27-5 3-(5-((1R)-1-[(tert-butoxycarbonyl)amino]-1-methyl-2-phenylethyl)-1,3,4-oxadiazol-2-yl)-5-[methyl(methylsulfonyl)amino]benzoic acid methyl ester 
• 868287-31-4 C₂₆H₃₁N₃O₇S 
• 868286-88-8 C₂₅H₃₀N₄O₆S₂ 
• 868286-28-6 3-(5-((1R)-1-[(tert-butoxycarbonyl)amino]-1-methyl-2-phenylethyl)-1,3,4-oxadiazol-2-yl)-5-[methyl(methylsulfonyl)amino]benzoic acid 

Relevant articles and documents

N3-SUBSTITUTED IMINOPYRIMIDINONES AS RENIN INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain N3-substituted iminopyrimidinones of Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoiso

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treat

ASPARTYL PROTEASE INHIBITORS

The invention provides compounds of the formula (I) N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein G is-O-, -S(=O)r-, -CRdRd or -NRa-; W is H, C1-C6

β SECRETASE INHIBITOR

Disclosed is a compound represented by the formula (1) below which is useful as a drug for treating Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents a group represented by the following formula (2): (2) (wherein X represents a nitrogen atom or a group expressed as C(R5); Y represents a nitrogen atom or a group expressed as C(R6); and R5 and R6 independently represent a hydrogen atom or the like) or the like; m represents an integer of 1-6; L1 represents a single bond or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; R3 represents a hydrogen atom or the like; L2 represents a single bond or the like; and R4 represents a hydrogen atom, a substituted or unsubstituted aryl group or the like.]

Design, synthesis, and X-ray structure of potent memapsin 2 (β-secretase) inhibitors with isophthalamide derivatives as the P 2 P3-ligands

Structure-based design and synthesis of a number of potent and selective memapsin 2 inhibitors are described. These inhibitors were designed based upon the X-ray structure of memapsin 2-bound inhibitor 3 that incorporates methylsulfonyl alanine as the Ps

Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides novel beta-secretase inhibitors of the general formula (I), where the variables A1, A2, L1, L2, L3, R1, R2, R3, R4, R5, R6 and R7 are as defined in the claims, a method for their use in treating Alzheimer's disease, and methods for their use in reducing memapsin 2 catalytic activity.

Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof

The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R1 to R15, A, B, L, i as well as X1-X4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

Conformationally biased P3 amide replacements of β-secretase inhibitors

We have synthesized and evaluated a series of conformationally biased P3 amide replacements based on an isophthalamide lead structure. The studies resulted in the identification of the β-secretase inhibitor 7m which has an in vitro IC50 = 35 nM